When was Anchiano Therapeutics founded?

Anchiano Therapeutics was founded in 2004.

Where is Anchiano Therapeutics located?

Anchiano Therapeutics is located in Cambridge, United States .

Who is the current CEO of Anchiano Therapeutics?

Frank Haluska is the current CEO of Anchiano Therapeutics.

How many employees does Anchiano Therapeutics have?

Anchiano Therapeutics has 5 employees as of Dec 31, 2021.

Where does Anchiano Therapeutics rank among its competitors?

Anchiano Therapeutics ranks 56 amongst 85 active competitors.

Who are the top competitors of Anchiano Therapeutics?

Anchiano Therapeutics' top competitors are Senti Biosciences, Poseida Therapeutics and Aldevron.

Anchiano Therapeutics - 2025 Company Profile, Funding & Competitors

Company Details

Developer of gene therapy for the treatment of bladder cancer. The company's product Inodiftagene vixteplasmid (BC-819) is using a targeted recombinant DNA-based gene construct that is engineered to express a lethal toxin specifically in malignant cells.

Website
Email ID: @anchiano.com
Phone Number: +1

Key Metrics

Founded Year

2004

Location

Cambridge, United States

Stage

Public

Investors

Springboard Enterprises

Ranked

56^th among

Employee Count

as on Dec 31, 2021

Similar Companies

Senti Biosciences &

Exit Details

Public

Legal entities associated with Anchiano Therapeutics

Anchiano Therapeutics is associated with 1 legal entity given below:

Legal Entity Name	Date of incorporation	Revenue	Net Profit	Employee Count
		-	881	503

Anchiano Therapeutics is a funded company.

Anchiano Therapeutics has 1 institutional investor - .

View details of Anchiano Therapeutics's funding rounds and investors

The founders of Anchiano Therapeutics is . is the CEO of Anchiano Therapeutics.

View details of Anchiano Therapeutics's Founder profiles and Board Members

Top competitors of Anchiano Therapeutics include Senti Biosciences, Poseida Therapeutics and Aldevron. Here is the list of Top 10 competitors of Anchiano Therapeutics, ranked by 秘密研究所 score :

Overall Rank	Company Details	Short Description	Total Funding	Investors	秘密研究所 Score
1st	Senti Biosciences 2016, San Francisco (United States), Public	Developer of cell-based therapies for cancer treatment	$158M	Amgen, Bioworld Ventures听&补尘辫;听	71/100
2nd	Poseida Therapeutics 2015, San Diego (United States), Acquired	Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies	$324M	Vivo Capital, Novartis听&补尘辫;听	66/100
3rd	Aldevron 1998, Fargo (United States), Acquired	Developer and custom manufacturer of nucleic acids, proteins and antibodies for research, clinical and commercial applications	-	CPP Investments, TA听&补尘辫;听	57/100
4th	UroGen Pharma 2004, Ra anana (Israel), Public	Developer of therapeutics to treat urothelial and specialty cancers	$7M	Monograph, Magna Capital Partners听&补尘辫;听	57/100
5th	CRISPR Therapeutics 2013, Basel (Switzerland), Public	Developer of solutions for treating human genetic diseases by using genome editing technology	$127M	Vertex Pharmaceuticals, Wellington听&补尘辫;听	57/100
6th	ADARx Pharmaceuticals 2019, San Diego (United States), Series C	Developer of genetic therapeutic solutions to edit single point mutations on RNA transcripts	$353M	Vivo Capital, BlackRock听&补尘辫;听	56/100
7th	Precision BioSciences 2006, Durham (United States), Public	Developer of gene editing therapies to treat rare genetic diseases	$136M	Vivo Capital, Cowen听&补尘辫;听	55/100
8th	Genprex 2009, Austin (United States), Public	Developer of therapeutics to treat cancer at molecular level	$3.11M	Inception Capital Management, NIH听&补尘辫;听	55/100
9th	Tome Biosciences 2021, Cambridge (United States), Series B	Developer of gene insertion platform for genomic medicines	$213M	Bruker, 听&补尘辫;听	54/100
10th	WhiteLab Genomics 2019, Paris (France), Series A	Provider of drug discovery and development platform	$10.2M	Debiopharm, Omnes Capital听&补尘辫;听	53/100
56th	2004, Cambridge (United States), Public	Developer of gene therapy for the treatment of bladder cancer	-	Springboard Enterprises	25/100